Pain Management · Opioid CombinationRegulatory Approvalregulatorynear-term

FDA Approval Status for Acetaminophen and Codeine Phosphate (ANDA211610)

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 6:35:14 AM

Assessment confidence: 58% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The FDA's approval of ANDA211610 for acetaminophen and codeine phosphate is significant as it strengthens HIBROW HLTHCARE's competitive position in the opioid combination segment. This approval necessitates strategic marketing and distribution efforts to leverage the opportunity effectively. Regulatory context from FDA (FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)) supports the near-term read. Assessment grounded in 14 ranked evidence items (5 high-relevance).

Strategic Assessment

Strategic focus on marketing and distribution strategies will be essential to capitalize on this approval and compete effectively. The strongest clinical anchor is Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain (ClinicalTrials.gov), sub-indication match (pain). In pain, 8 regulatory and 2 competitive items passed relevance filtering for HIBROW HLTHCARE.

Competitive Pressure

The most relevant competitive pressure comes from FDA Approval for Oxycodone Hydrochloride by Novel Labs (Humanexa Signals) — sub-indication match (pain). Secondary pressure from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need. This approval may enhance HIBROW HLTHCARE's position in the pain management market, particularly in the opioid combination segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL) (FDA). Entity match (hibrow hlthcare); Regulatory pathway relevance (nda). The 'AP' status indicates a favorable regulatory outcome, but ongoing compliance and market launch strategies will be crucial to maintain this status.

Key Risks

Elevated medium regulatory exposure for HIBROW HLTHCARE could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The approval could lead to increased market share for HIBROW HLTHCARE in the pain management sector, impacting revenue positively if marketed effectively.
Strategic focus on marketing and distribution strategies will be essential to capitalize on this approval and compete effectively.

What Would Change This Assessment

This becomes more urgent if Monitor for further updates on market launch and any competitive responses from other opioid combination products.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond near term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (hibrow hlthcare); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (acetaminophen and codeine phosphate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Entity match (acetaminophen and codeine phosphate); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — FIORICET W/ CODEINE (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View source

Evaluation of Medical Cannabis and Prescription Opioid Taper Support for Reduction of Pain and Opioid Dose in Patients With Chronic Non-Cancer Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Effect of Nociception Level Monitoring During Remimazolam-based Total Intravenous Anesthesia on Intraoperative Opioid Requirements and Postoperative Pain
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Evaluation of the Japet.W+ Medical Device for Low Back Pain Management
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
ClinicalTrials.govhigh relevance
Sub-indication match (pain)
FDA document
View source
Liposomal Bupivacaine Plus Plain Bupivacaine Versus Dexamethasone Plus Plain Bupivacaine in the Supraclavicular Brachial Plexus Block in Patients With Risk Factors for Severe Acute Postoperative Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Effects of Music Therapy in Chronic Neck Pain
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Comparative Outcomes of Inj Botox Alone vs Inj Botox Combined With Fissurectomy and Anoplasty in the Management of Chronic Anal Fissure
ClinicalTrials.govlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

FDA Approval for Oxycodone Hydrochloride by Novel Labs
Humanexa Signalshigh relevance
Sub-indication match (pain)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizermedium relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalslow relevance
Sponsor/company relevance (Roche)

Immunogenicity and safety of a 2 + 1 schedule of the DTaP-IPV-HB-Hib hexavalent combination vaccine in preterm infants in Spain.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Factors predicting health-enhancing physical activity in patients with chronic widespread pain following a person-centred health plan.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedlow relevance
Weak alignment to signal sub-indication and entities
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

HIBROW HLTHCARE
acetaminophen and codeine phosphate

Commercial impact

medium

The approval could lead to increased market share for HIBROW HLTHCARE in the pain management sector, impacting revenue positively if marketed effectively.

Regulatory impact

medium

The 'AP' status indicates a favorable regulatory outcome, but ongoing compliance and market launch strategies will be crucial to maintain this status.

What to watch

Monitor for further updates on market launch and any competitive responses from other opioid combination products.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.